Inclusion Criteria:

   - Patients must satisfy all the following criteria for entry into the protocol:

Primary CBCL including (according to WHO/EORTC classification 2005) :

   - Primary cutaneous marginal zone B-cell lymphoma

   - Primary cutaneous follicle center B-cell lymphoma

   - Primary cutaneous diffuse large B-cell other than leg type

      - Histologically consistent with primary CBCL.

      - Relapse or active disease after radiotherapy or other adequate therapy if
      radiotherapy was contra-indicated (chemotherapy, surgical excision, interferonα,
      rituximab).

      - Performance status of 0, 1 on the Eastern Cooperative Oncology Group (ECOG) scale
      (See Appendix E).

      - Minimum Life Expectancy > 3 months.

      - Adequate blood count: hemoglobin >= 10.0 g/dL; White Blood Count (WBC) >= 3.0 x
      109/L; and platelet count >= 75 x 109/L.

      - Adequate hepatic function: bilirubin =< 1.5 times the upper limit of normal and
      serum transaminase (SGOT and SGPT)=< 2.5 times the upper limit of normal.

      - Adequate renal function: creatinine =< 1.5 times the upper limit of normal.

      - Written informed consent from patient.

Exclusion Criteria:

Patients will be excluded from the study for any of the following reasons:

   - Primary cutaneous diffuse large B-cell lymphoma, leg type.

   - Primary cutaneous intravascular large B-cell lymphoma.

   - Extracutaneous involvement (sign of B-cell lymphoma on thoraco-abdominal CT scan
   and/or PET scan and/or on bone marrow biopsy).

   - No histologic documentation of CBCL.

   - History of known Human Immuno-deficiency Virus, Human Hepatitis B or C positive
   serology or other active systemic infections.

   - Serious uncontrolled, concomitant medical disorders.

   - Concomitant therapy for CBCL: surgical resection, radiotherapy, corticosteroid,
   chemotherapy, rituximab…(not limited listing)

   - Major surgery in previous 4 weeks preceding the 1st injection.

   - Pregnancy at study entry or who become pregnant during the study or women who are
   breast feeding.

   - Males and females of reproductive potential who refuse to use adequate protection
   against pregnancy (intra-uterine device, hormonal contraception or diaphragm/condom
   and spermicide) during the conduct of the study and for three months after the last
   injection.

   - Participation in another experimental protocol during the study period and within 4
   weeks prior to the first injection.

   - Patient previously included in this study.

   - Non compliance with the study.